[{"orgOrder":0,"company":"Rinri Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Rinri Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rinri Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Rinri Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Rinri Therapeutics","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Rinri Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rinri Therapeutics \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Rinri Therapeutics \/ Innovate Biopharmaceuticals"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : This grant will fund a £3.2 million project to further develop Rinri’s novel stem cell therapy to reverse sensorineural hearing loss (SNHL) an area / a condition where there remains a significant global unmet need.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 13, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Preclinical

                          Sponsor : Innovate Biopharmaceuticals

                          Deal Size : $4.5 million

                          Deal Type : Funding

                          blank

                          02

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : The proceeds will support the development of the Company's novel stem cell therapy to reverse sensorineural hearing loss (SNHL).

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 20, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Preclinical

                          Sponsor : Boehringer Ingelheim GmbH

                          Deal Size : $14.1 million

                          Deal Type : Financing

                          blank